The Legal Issues Regarding the Reimbursement of Drugs Used to Treat Muscular Atrophy and the Actual Situation in the Slovak Republic

This article explores the legal problems regarding reimbursing drugs used to treat muscular atrophy. The article highlights the importance of insurance coverage for patients with muscular atrophy and the need for more uniform policies. In the Slovak Republic, the state health insurance company refused to reimburse the medicine several times, although it made an exception for other children in the past. The patient asked the civil court to order an urgent measure. The court granted this proposal and ordered the insurance company to pay for the drug Zolgensma. The article analyzes the legal nature of this case considering fundamental human rights.